search
Back to results

Comparing Cefepime Versus Cefazolin Plus Ceftazidime for CAPD-associated Peritonitis

Primary Purpose

Peritoneal Dialysis Associated Peritonitis

Status
Completed
Phase
Phase 4
Locations
Thailand
Study Type
Interventional
Intervention
Cefepime
Cefazolin plus Ceftazidime
Sponsored by
Chulalongkorn University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peritoneal Dialysis Associated Peritonitis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age more than 18 years
  • CAPD initiation more than 4 weeks

Exclusion Criteria:

  • Exit site or tunnel infection
  • Sepsis
  • Previous CAPD-associated peritonitis treatment within 4 weeks
  • Drug allergy to cephalosporin
  • Tenckhoff catheter malfunction
  • Hospitalization more than 48 hours
  • Fungal or Mycobacterium infection
  • Suspected secondary peritonitis
  • Concomitant antibiotics.

Sites / Locations

  • Chulalongkorn University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Treatment

Control

Arm Description

Cefepime intraperitoneal continuous dosing

Cefazolin plus Ceftazidime intraperitoneal continuous dosing

Outcomes

Primary Outcome Measures

Primary response rate
Resolution of clinical peritonitis and peritoneal dialysis fluid WBC < 100 /μL with PMN < 50% at day 10

Secondary Outcome Measures

Initial response rate
Resolution of clinical peritonitis and peritoneal dialysis fluid WBC < 100 /μL with PMN < 50% at day 5

Full Information

First Posted
July 25, 2016
Last Updated
October 30, 2017
Sponsor
Chulalongkorn University
Collaborators
The Kidney Foundation of Thailand, Siam Pharmaceutical Co Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT02872038
Brief Title
Comparing Cefepime Versus Cefazolin Plus Ceftazidime for CAPD-associated Peritonitis
Official Title
A Multicenter, Randomized, Controlled Trial Comparing Cefepime Monotherapy Versus Combination of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-associated Peritonitis
Study Type
Interventional

2. Study Status

Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
August 2015 (undefined)
Primary Completion Date
November 30, 2016 (Actual)
Study Completion Date
November 30, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chulalongkorn University
Collaborators
The Kidney Foundation of Thailand, Siam Pharmaceutical Co Ltd

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to compare the efficacy of empirical antibiotics of CAPD-associated peritonitis with intraperitoneal, continuous dosing of cefepime monotherapy versus combination of cefazolin and ceftazidime. Patients were randomized to be administered either intraperitoneal cefepime 1 g loading then 250 mg all exchanges (treatment group) or cefazolin and ceftazidime (control group) in the same dose.
Detailed Description
The International Society of Peritoneal Dialysis (ISPD) guideline suggest to use combination of antibiotics to cover both of gram positive and gram negative bacteria. The usual regimen in Thailand is cefazolin plus ceftazidime. Despite combination therapy, monotherapy is also possible for empirical treatment of CAPD-associated peritonitis since it helps to lowering staff burden and lowering risk of contamination. Cefepime could be an ideal antibiotic for empirical treatment of CAPD-associated peritonitis as it is an extended-spectrum cephalosporin, forth generation, covering most of gram positive and gram negative bacteria. In addition, cefepime is not broken down by many of the beta-lactamases and less beta-lactamases inducer. This study aims to prove the noninferiority of cefepime monotherapy to cefazolin plus ceftazidime for empirical treatment of CAPD-associated peritonitis. CAPD-associated peritonitis was diagnosed by at least two of the following criteria: abdominal pain or cloudy peritoneal dialysis fluid (PDF); PDF white cell count > 100/μL with > 50% polymorphonuclear(PMN); and positive gram stain or culture. The patients were randomized into two groups by block of four randomization, sealed envelope. Treatment group was treated with intraperitoneal (IP) cefepime 1 g loading following by maintenance dose 250 mg IP all exchanges. Control group was treated with cefazolin 1 g IP loading and ceftazidime 1 g IP loading following by maintenance dose of cefazolin and ceftazidime 250 mg IP all exchanges. If a patient had residual urine ≥ 100 ml/day, dose of antibiotics would be increased by 25%. On the first day, the initial blood tests for complete blood count, electrolyte, BUN, creatinine, calcium, phosphate and magnesium were obtained. While peritoneal dialysis fluid were collected using two methods of bacterial culture, both of centrifugation of 50 ml peritoneal dialysis fluid at 3,000 g for 15 minutes and bedside 5-10 ml of peritoneal dialysis fluid inoculated into the blood culture bottles. PDF gram stain and bacterial culture were done. The patients were followed on day 3, 5, 10, 14, 21 and 28 days after the completion of antibiotic course. If clinical improved, the antibiotics would be adjusted according to the culture result and sensitivity after day 5. If clinical not improved the antibiotics would be step up and Tenckhoff catheter removal was considered (on any day of treatment). The patients were treated at least 14 days or 21 days depend on the culture result (as the recommendation of ISPD guideline 2010).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peritoneal Dialysis Associated Peritonitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
154 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Experimental
Arm Description
Cefepime intraperitoneal continuous dosing
Arm Title
Control
Arm Type
Active Comparator
Arm Description
Cefazolin plus Ceftazidime intraperitoneal continuous dosing
Intervention Type
Drug
Intervention Name(s)
Cefepime
Intervention Description
Cefepime intraperitoneal continuous dosing
Intervention Type
Drug
Intervention Name(s)
Cefazolin plus Ceftazidime
Other Intervention Name(s)
Control group
Primary Outcome Measure Information:
Title
Primary response rate
Description
Resolution of clinical peritonitis and peritoneal dialysis fluid WBC < 100 /μL with PMN < 50% at day 10
Time Frame
day 10 of treatment
Secondary Outcome Measure Information:
Title
Initial response rate
Description
Resolution of clinical peritonitis and peritoneal dialysis fluid WBC < 100 /μL with PMN < 50% at day 5
Time Frame
day 5 of treatment
Other Pre-specified Outcome Measures:
Title
Complete cure rate
Description
Complete resolution without relapse or recurrent within 28 days after completion of antibiotics.
Time Frame
28 days after completion of antibiotics
Title
Relapse peritonitis rate
Description
Recur of peritonitis with the same organism or sterile culture within 28 days after completion antibiotics
Time Frame
28 days after completion antibiotics
Title
Recurrent peritonitis rate
Description
Recur of peritonitis with different organism within 28 days after completion antibiotics
Time Frame
28 days after completion antibiotics
Title
Death rate
Description
Death from any cause
Time Frame
28 days after completion antibiotics

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age more than 18 years CAPD initiation more than 4 weeks Exclusion Criteria: Exit site or tunnel infection Sepsis Previous CAPD-associated peritonitis treatment within 4 weeks Drug allergy to cephalosporin Tenckhoff catheter malfunction Hospitalization more than 48 hours Fungal or Mycobacterium infection Suspected secondary peritonitis Concomitant antibiotics.
Facility Information:
Facility Name
Chulalongkorn University
City
Bangkok
ZIP/Postal Code
10500
Country
Thailand

12. IPD Sharing Statement

Citations:
PubMed Identifier
31331757
Citation
Kitrungphaiboon T, Puapatanakul P, Chuengsaman P, Tiskajornsiri K, Halue G, Siribamrungwong M, Matayart S, Chongthanakorn K, Poonvivatchaikarn U, Boonyakrai C, Somboonsilp W, Katavetin P, Praditpornsilpa K, Eiam-Ong S, Johnson DW, Kanjanabuch T. Intraperitoneal Cefepime Monotherapy Versus Combination Therapy of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-Associated Peritonitis: A Multicenter, Open-Label, Noninferiority, Randomized, Controlled Trial. Am J Kidney Dis. 2019 Nov;74(5):601-609. doi: 10.1053/j.ajkd.2019.05.011. Epub 2019 Jul 19.
Results Reference
derived

Learn more about this trial

Comparing Cefepime Versus Cefazolin Plus Ceftazidime for CAPD-associated Peritonitis

We'll reach out to this number within 24 hrs